Last reviewed · How we verify
NCT03778268: SLNMICC
Sentinel Lymph Node Mapping In Cervical Cancer
NA trial testing sentinel lymph node biopsy in Uterine Cervical Neoplasms in 1,143 participants. Status unknown.
30 June 2020
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 1,143 |
| Start date | 15 December 2018 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 2 locations across China |
Drugs / interventions tested
- sentinel lymph node biopsy
Conditions studied
- Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →
Sponsor
Peking University People's Hospital
Who can join
Adults 18 to 80, female only, with Uterine Cervical Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lymph node assessment provides the crucial information about the prognosis of cervical cancer. Sentinel lymph node stands in the first station on the lymph node metastasis pathways. While traditional systemically lymph node resection would bring a lot of complications, sentinel node mapping and biopsy is a feasible way with less damage to evaluate whether lymph node metastasis occurs in early cervical cancer patients, due to less lymph nodes resected. However, the process of this technology isn't well established. The investigators intend to conduct a prospective and multicentric study to evaluate the effectiveness of different mapping methods to achieve a reliable lymph node assessment. Early cervical cancer patients in each center will be recruited in the investigators' study with inclusion and exclusion criteria. After the patients signing the informed consent form, the surgery process will be performed, including sentinel lymph node mapping with Carbon Nanoparticles (CNP) or CNP combining Indocyanine Green(ICG), extra-fascial/sub-extensive/extensive hysterectomy, pelvic with or without para-aortic lymph node resection, sequentially. All resected nodes will be pathologically exanimated. Then the data obtained will be analyzed and discussed deeply and finally lead to a conclusion.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nanotechnology in cancer diagnosis: progress, challenges and opportunities.
Zhang Y, Li M, Gao X, Chen Y, et al · · 2019 · cited 227× · PMID 31847897 · DOI 10.1186/s13045-019-0833-3 -
Image-guided tumor surgery: The emerging role of nanotechnology.
Wojtynek NE, Mohs AM. · · 2020 · cited 34× · PMID 32162485 · DOI 10.1002/wnan.1624
Verify or expand the search:
- PubMed search for NCT03778268
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of sentinel lymph node biopsy
Trials testing the same drug.
- NCT07098507 — De-escalation in Axillary Surgery for Early-stage Breast Cancer · NA · not yet recruiting
- NCT06706726 — To Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection Combined With Imme · NA · not yet recruiting
- NCT06169787 — Sentinel Lymph Nodes Biopsy in Cervical Cancer · active not recruiting
- NCT03647631 — Sentinel Lymph Node Biopsy in Porocarcinoma · completed
- NCT01826864 — Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma · Phase 3 · withdrawn
Other recruiting trials for Uterine Cervical Neoplasms
Currently open trials in the same condition.
- NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting
- NCT07011836 — Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women · NA · recruiting
- NCT06815939 — Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer · NA · recruiting
- NCT06558682 — Neoadjuvant Therapy in Cervical Cancer · NA · recruiting
- NCT06509724 — Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy · Phase 3 · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03778268 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 19 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03778268.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing